Home
/
Larimar Therapeutics, Inc.
/
Financials
/
Quarterly
Larimar Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Larimar Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2020
Mar 31, 2020
$0
May 7, 2020
Q3
2019
Sep 30, 2019
$0
Nov 6, 2019
Q2
2019
Jun 30, 2019
$0
Aug 8, 2019
Q1
2020
Mar 31, 2019
$0
May 7, 2020
Q3
2019
Sep 30, 2018
$0
Nov 6, 2019
Q2
2019
Jun 30, 2018
$0
Aug 8, 2019
Q1
2019
Mar 31, 2018
$0
May 9, 2019
Q3
2018
Sep 30, 2017
$0
Nov 9, 2018
Q2
2018
Jun 30, 2017
$0
Aug 9, 2018
Q1
2018
Mar 31, 2017
$0
May 10, 2018
Q3
2017
Sep 30, 2016
$0
Nov 7, 2017
Q2
2017
Jun 30, 2016
$0
Aug 9, 2017
Q1
2017
Mar 31, 2016
$0
May 9, 2017
Q3
2016
Sep 30, 2015
$0
Nov 9, 2016
Q2
2016
Jun 30, 2015
$0
Aug 5, 2016
Q1
2016
Mar 31, 2015
$0
May 10, 2016
Q3
2015
Sep 30, 2014
$0
Nov 13, 2015
Q2
2015
Jun 30, 2014
$0
Aug 14, 2015
Q1
2015
Mar 31, 2014
$0
May 14, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($47.71M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($26.18M)
Aug 14, 2025
Q3
2025
Jun 30, 2025
($26.18M)
Nov 5, 2025
Q3
2025
Mar 31, 2025
($29.28M)
Nov 5, 2025
Q1
2025
Mar 31, 2025
($29.28M)
Apr 30, 2025
Q2
2025
Mar 31, 2025
($29.28M)
Aug 14, 2025
Q3
2025
Sep 30, 2024
($15.50M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($21.63M)
Aug 14, 2025
Q3
2025
Jun 30, 2024
($21.63M)
Nov 5, 2025
Q2
2025
Mar 31, 2024
($14.65M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($14.65M)
Apr 30, 2025
Q3
2025
Mar 31, 2024
($14.65M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
($9.06M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($8.37M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($8.37M)
Oct 30, 2024
Q1
2024
Mar 31, 2023
($6.53M)
May 9, 2024
Q3
2024
Mar 31, 2023
($6.53M)
Oct 30, 2024
Q2
2024
Mar 31, 2023
($6.53M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($8.32M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($8.67M)
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($49.50M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($27.79M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($31.19M)
Apr 30, 2025
Q3
2025
Sep 30, 2024
($18.26M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($24.60M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($16.73M)
Apr 30, 2025
Q3
2024
Sep 30, 2023
($10.34M)
Oct 30, 2024
Q2
2024
Jun 30, 2023
($9.62M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($7.64M)
May 9, 2024
Q3
2023
Sep 30, 2022
($8.51M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($8.69M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($8.89M)
May 15, 2023
Q3
2022
Sep 30, 2021
($16.73M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($12.54M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($12.11M)
May 12, 2022
Q3
2021
Sep 30, 2020
($10.34M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($11.40M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($6.67M)
May 10, 2021
Q3
2020
Sep 30, 2019
($8.63M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($3.70M)
Aug 14, 2020